Pengaruh Pemberian Esomeprazole Terhadap Ekspresi Imunohistokimia Soluble Fms-Like Tyrosine Kinase (Sflt-1) Dan Soluble Endoglin (Seng) Pada Tikus Dengan Model Preeklamsia
Abstract
Preeclampsia is a systemic disorder affecting approximately 3–8% of pregnant women, occurring during or after pregnancy. The exact cause and underlying mechanisms of this condition remain unclear. It is believed that the anti-angiogenic molecules soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng), which are excessively produced by the placenta in preeclampsia, play a significant role in endothelial dysfunction. Recent studies suggest that esomeprazole, a proton pump inhibitor, is generally well tolerated in preeclamptic patients. This study aimed to evaluate the effect of esomeprazole administration on the reduction of sFlt-1 and sEng expression in a preeclampsia-induced rat model using an analytical approach with a quasi-experimental design. The research was conducted at two laboratories within the Faculty of Medicine and the Faculty of Mathematics and Natural Sciences at Universitas Sumatera Utara: the Anatomical Pathology Laboratory and the Biology Laboratory. The study subjects consisted of 30 healthy and active female laboratory rats (Rattus norvegicus), aged 10 weeks, modeled to resemble preeclamptic conditions. The study was carried out in May 2021. After the intervention, significant differences were observed between the intervention and control groups in systolic blood pressure, diastolic blood pressure, and mean arterial pressure (MAP) (p = 0.001; p = 0.014; p = 0.001). Additionally, the proportion of proteinuria was lower in the intervention group than in the control group. The mean expression levels of sFlt-1 and sEng also showed statistically significant differences between the intervention and control groups (p = 0.002; p = 0.001). The findings indicate statistically significant changes in MAP, systolic and diastolic blood pressure, and proteinuria across all groups following the intervention. A comparison of sFlt-1 and sEng expression levels among the negative control, positive control, and intervention groups revealed statistically significant differences. Esomeprazole administration at a dosage of 4.68 mg/kgBW/day significantly reduced sFlt-1 expression, demonstrating the therapeutic potential of esomeprazole in suppressing anti-angiogenic factors in preeclampsia.
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Pusat Data dan Informasi Kementrian Kesehatan RI. InfoDATIN. Kementrian Kesehatan RI. 2014.
Stalker P. Kita suarakan MDGs demi pencapaiannya di Indonesia. Badan Perencanaan Pembangunan Nasional. 2008.
Kementrian Kesehatan Republik Indonesia. Rencana strategis Kementrian Kesehatan Tahun 2015 – 2019. Keputusan Kementrian Kesehatan Republik Indonesia. 2015.
Loisel DA, Billstrand C, Murray K, Patterson K, Chaiworapongsa T, Romero R, Ober C., The maternal HLA-G 1579 C null mutation is associated with increased risk of pre-eclampsia and reduced HLA-G expression during pregnancy in African-American women. Molecular Human Reproduction. 2013; 19(3):144-52.
Girsang, Elizabeth, et al., Analisis tekanan darah dan peroteinuria sebagai faktor prognosis kematian maternal dan perinatal pada preeklamsia berat dan eklampsia, repository.usu.ac.id, 2014: h 1-68.
World Health Organization (WHO). Dibalik angka – Pengkajian kematian maternal dan komplikasi untuk mendapatkan kehamilan yang lebih aman. Indonesia:WHO;2007.
Badan Perencanaan dan Pembangunan Nasional. Report on achievement of millenium development goals Indonesia. Jakarta: Bappenas; 2010:67.
Nursal DG, Tamela P, Fitrayeni. Faktor risiko kejadian preeklamsia pada ibu hamil di RSUP DR. M. Djamil Padang Tahun 2014. Jurnal Kesehatan Masyarakat Andalas. 2015;10(1):38-44. 10. Girsang, ES. Analisa Tekanan Darah dan Proteinuria sebagai Faktor Prognos.
Rossa. 2006. In: Resmi AS. Faktor yang berhubungan dengan Preeklamsia pada Kehamilan di RSU Muhammadiyah Sumatera Utara Medan 2011-2012. Medan: Repository Universitas Sumatera Utara. 2014. Available from: http://repository.usu.ac.id/bitstream/handle/12345.
Dinas Kesehatan Provinsi Sumatera Utara. 2011. In: Resmi AS. Faktor yang berhubungan dengan preeklamsia pada kehamilan di RSU Muhammadiyah Sumatera Utara Medan 2011-2012. Medan: Repository Universitas Sumatera Utara. 2014. Available from: http://repositor.
Cluver, CA et al. Double Blind, Randomised, Placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset preeclampsia (PIE Trial): a Study Protocol. BMJ Open 2015: 5; 1-8.
UNMDG. http://www.un.org/milleniumgoals/ accessed at [February 26th 2019].
Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: Executive Summary. Journal of Obstetrics Gynecology Canada. 2014: 36(5);416-438.
Cluver CA, Hannan NJ, van Papendorp E, Hiscock R, Beard S, Mol BW, et al. Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial. Am J Obstet Gynecol. 2018 Oct;219(4):388.e1-388.e17. doi: 10.1016/j.ajog.2018.07.019.
Onda K, Tong S, Beard S, Binder N, Muto M, Senadheera SN, et al. Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction. Hypertension. 2017 Mar;69(3):457-468.
Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA. Soluble Fms-like tyrosine kinase 1 and endothelial. dysfunction in the pathogenesis of preeclampsia. International Pediatric Research Foundation. 2005.
Ma’ayeh, M., Rood, K.M., Kniss, D., Costantine, M.M. Novel interventions for the prevention of preeclampsia. Curr Hypertens Rep 2020; 22.
Hastie R, Bergman L, Cluver CA, Wikman A, Hannan NJ, Walker SP, Wikström AK, Tong S, Hesselman S. Proton Pump Inhibitors and Preeclampsia Risk Among 157 720 Women. Hypertension. 2019 May;73(5):1097-1103.
Lisbôa MBM de C, Oliveira EO, Lamounier JA, Silva CAM, Freitas RN. Prevalence of iron-deficiency anemia in children aged less than 60 months: A population-based study from the state of Minas Gerais, Brazil. Rev Nutr. 2015;28(2):121–31.
De Silva, M., Brownfoot, F., Hannan, N.J., Walker, S.P., Cluver, C.A., Lindquist, et al. A Systematic review of proton pump inhibitors for the prevention and treatment of preeclampsia and gestational hypertension. OJOG. 2019; 09(1): 21–28.
Refbacks
- There are currently no refbacks.